17 hrs ago
Eisai's Named Patient Access Programme for FycompaA (perampanel) Available from 1 January 2014
The named patient access programme will be managed by Clinigen Global Access Programs , part of Clinigen Group plc and will ensure that all patients on the programme continue to receive an uninterrupted supply of FycompaA at no cost to the German healthcare system.
Home Testing Devices Could Monitor EpilepsyDrug Levels, Reduce Clinical Visits
WASHINGTON D.C., December 9, 2013- Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures , or convulsions, during activities of daily living.
Mon Dec 09, 2013
SAGE Therapeutics Presents New Data Identifying Highly Selective,...
SAGE Therapeutics , a biopharmaceutical company developing novel medicines to treat central nervous system diseases, today announced new data presented at the American Epilepsy Society Annual Meeting that reveal a novel mechanism and approach for the treatment of status epilepticus and identify new, orally bioavailable compounds that may lead to ... (more)
Eisai Announces New Partnership with Esteve to Promote Anti-epilepsy...
Eisai announces today that it has selected Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to become its epilepsy partner in to promote ZonegranA .
Extended-Release Topiramate Shows Promise in Late-Stage Epilepsy Trial
Positive results have been reported from a global phase III study of extended-release topiramate .
Applied Clinical Trials
Upsher-Smith Debuts Positive Results From Global Phase 3 Study...
Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 In Epilepsy Patients With Refractory Partial-Onset Seizures Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 In Epilepsy Patients With Refractory Partial-Onset Seizures /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today presented ... (more)
Acorda Therapeutics presents new data on Diazepam nasal spray
Acorda Therapeutics presents new data on Diazepam nasal spray Acorda Therapeutics announced that new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics whether the drug was administered during or immediately after a seizure.
Fri Dec 06, 2013
SUDEP is an uncommon danger of epilepsy
Dear Dr. Roach: At the age of 19, our son started having seizures in his sleep. The first one was a grand mal seizure, and we were able to get him to the hospital.
Tuberous Sclerosis Complex Clinic earns specialty designation
The Tuberous Sclerosis Complex Clinic at Lucile Packard Children's Hospital has earned a specialty designation from the Tuberous Sclerosis Alliance.
Sunovion Pharmaceuticals Inc. to Present New Data on Aptiom...
Sunovion Pharmaceuticals Inc. to Present New Data on Aptiom A at The American Epilepsy Society's 67 th Annual Meeting )--Sunovion Pharmaceuticals Inc. will present new research posters on AptiomA and data on antiepileptic drug use in the U.S. managed care population at the 67th Annual Meeting of the American Epilepsy Society taking place December ... (more)
Wed Dec 04, 2013
Mother Calls for Legalization of Cannabis Oil to Help Daughter's Seizures
A Madison family is pleading for help for their 16 month old baby girl. Charlotte Dalton has seizures almost daily, some lasting almost an hour long.
Tue Dec 03, 2013
Onfi (clobazam): Drug Safety Communication - Risk of Serious Skin Reactions
ISSUE : FDA is warning the public that the anti-seizure drug Onfi can cause rare but serious skin reactions that can result in permanent harm and death.
Sat Nov 23, 2013
Salt Lake Tribune
Op-ed: Cannabidiol for epilepsy is unproven therapy
There are currently mixed messages about cannabidiol - Realm Oil. Is it a medication, supplement or drug? Others are also talking about medical cannabis for pain, appetite stimulation and nausea treatment.
Wed Nov 20, 2013
New Data From s Epilepsy Portfolio To Be Highlighted At The 67th...
New Data From UCB 's Epilepsy Portfolio To Be Highlighted At The 67th Annual Meeting Of The American Epilepsy Society /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at the 67th Annual Meeting of the American Epilepsy Society in , December 610.
The Town Talk
Roach: SUDEP a danger for epileptics
The first one was a grand mal seizure, and we were able to get him to the hospital.
Mon Nov 18, 2013
Applied Clinical Trials
Upsher-Smith To Present New Research On USL255 (Extended-Release...
Multiple Presentations Highlight Findings from Phase 3 Trial Investigating USL255 for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures Multiple Presentations Highlight Findings from Phase 3 Trial Investigating USL255 for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures ... (more)
Sun Nov 17, 2013
Drug shows early promise in treating seizures
A study out today in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure.
Delving Into Jewish Roots for Source of Her Epilepsy
When I started having seizures at the age of 7, no one ever suggested an exorcism.
Thu Nov 14, 2013
Parent's online petition urges Bentley, lawmakers to support medicinal marijuana for treating seizures
Dustin Chandler, a Pelham police officer, with wife Amy and daughter Carly meet with Gov. Robert Bentley in Montgomery on Oct. 28, 2013, to raise awareness of a rare genetic disorder called CDKL5 and generate support for medicinal marijuana that could help control seizures in patients.
FDA Approves Aptiom (Eslicarbazepine) to Treat Seizures in Adults
The FDA has approved Aptiom as an add-on medication to treat seizures associated with epilepsy.